Charlotte, North Carolina–(Newsfile Corp. – February 25, 2022) – cbdMD, Inc. (NYSE American: YCBD) (NYSE American: YCBDpA), (the “Company”) one of the world’s leading and most highly trusted and recognized health & wellness CBD companies, today announced it has entered into an endorsement agreement with 7-time NASCAR Cup Series (NCS) Champion and current NTT INDYCAR SERIES driver Jimmie Johnson as a strategic brand ambassador in the marketplace.
As the first and only CBD company to earn the highly respected designation of NSF Certified for Sport®, which opens the door to acceptance by major sports leagues in the USA and internationally, cbdMD was also just approved by INDYCAR to engage in sponsorship in 2022. Meeting the rigorous Certified for Sport® requirements, cbdMD is demonstrating commitment to clean sport and delivering quality products through safe and good manufacturing processes.
This unprecedented, multi-year deal serves as a unique opportunity to introduce the brand to INDYCAR fans with an iconic racer like Jimmie Johnson, further leveraging the partnership to activate across Food, Drug, Mass Merchant and Convenience (FDMC) retailers.
cbdMD Welcomes Jimmie Johnson
To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/8580/114728_dfde3fb5c40ebb31_001full.jpg.
“We are thrilled that Jimmie Johnson will be joining our Team cbdMD portfolio of athletes. Jimmie represents the very best in motorsport and brings a new level of acceptance in the marketplace for our brand. Working closely with Jimmie, we will share his personal story of ‘muscle recovery’ throughout the year and how cbdMD has played a key role in the process – especially leading into his first Indianapolis 500 Mile Race coming up in May,” said co-CEO of cbdMD, Inc. Martin Sumichrast.
“I’m excited to be part of Team cbdMD,” said Jimmie Johnson, who will be competing in his first full-time season in INDYCAR. “As a competitive athlete, it’s important to take care of your body. cbdMD has introduced several products that help me with muscle recovery. I’m looking forward to sharing my experiences with cbdMD, allowing me to compete at the highest level possible.”
About cbdMD, Inc.
cbdMD, Inc. is one of the leading and most highly trusted and recognized cannabidiol (CBD) brands with a comprehensive line of U.S.-produced, THC-free1 CBD products. The cbdMD brand currently includes over 130 SKUs of high-grade, premium CBD products including CBD tinctures, CBD gummies, CBD topicals, CBD capsules, CBD bath bombs, CBD bath salts, CBD sleep aids, CBD drink mixes and full spectrum CBD options. Our Paw CBD brand of pet products includes over 45 SKUs of veterinarian-formulated products including tinctures, chews and topical products in varying strengths, and our cbdMD Botanicals brand of beauty and skincare products features 15 SKUs, including facial oil and serum, toner, moisturizers, facial masks, exfoliants and body care. To learn more about cbdMD and their comprehensive line of U.S.-grown, THC-free1 CBD oil and full spectrum products, please visit www.cbdmd.com, follow cbdMD on Instagram and Facebook or visit one of the 6,000 retail outlets that carry cbdMD products.
Forward-Looking Statements
This press release contains certain forward-looking statements that are based upon current expectations and involve certain risks and uncertainties within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements can be identified by the use of words such as ”should,” ”may,” ”intends,” ”anticipates,” ”believes,” ”estimates,” ”projects,” ”forecasts,” ”expects,” ”plans” and ”proposes.” These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, some of which are beyond our control and difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements, including, without limitation, statements made with respect to the expansion of the consumer market for CBD products, our ability to increase our market share, the availability of the Amazon platform for our CBD products, our ability to expand our business and significantly increase our revenues, our ability to effectively leverage our brand partnerships and sponsorships, our ability to effectively compete in our market, our ability to achieve our net sales guidance, and our ability to report profitable operations in the future. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” in cbdMD, Inc.’s Annual Report on Form 10-K for the fiscal year ended September 30, 2021 as filed with the Securities and Exchange Commission (the “SEC”) and our other filings with the SEC. All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, many of which are generally outside the control of cbdMD, Inc. and are difficult to predict. cbdMD, Inc. does not undertake any duty to update any forward-looking statements except as may be required by law. The information which appears on our websites and our social media platforms, including, but not limited to, Instagram and Facebook, is not part of this press release.
1 THC-free is defined as below the level of detection using validated scientific methods.
Contacts:
PR:
cbdMD, Inc.
Robert Pettway
Director of Public Relations
rpettway@cbdmd.com
(423) 503-5225
Investors:
cbdMD, Inc.
John Weston
Director of Investor Relations
john.weston@cbdmd.com
(704) 249-9515
JJR, Inc:
Jimmie Johnson Racing, Inc.
Amy Stock
Director Communications
amy@jjracinginc.com
(704) 451-8380
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/114728
At 14-months median follow-up in the pivotal trial, 50% of patients achieved a complete response…
Objective response rate of 69.2% observed in heavily pretreated patient population including patients with BTK…
The study met its primary endpoint of overall survival with a 41% reduction in the…
DENVER, CO / ACCESSWIRE / June 15, 2024 / Each year over 120,000 Coloradans are…
REYKJAVIK, Iceland, June 15, 2024 /PRNewswire/ -- In a recent display of global baking talent,…
– ENERGIZE is the First Study to Demonstrate Efficacy of an Oral Treatment for Non-Transfusion-Dependent Alpha-…